Research Areas

  • Mechanisms of tumor growth and progression
  • Precision nanotherapeutics
  • Biomarker medicine



Dr. Marsha A. Moses is the Julia Dyckman Andrus Professor at Harvard Medical School and the Director of the Vascular Biology Program at Boston Children's Hospital. She is internationally recognized for her significant contributions to our understanding of the biochemical and molecular mechanisms that underlie the regulation of tumor development and progression. Dr. Moses and her laboratory have discovered several inhibitors of these processes that function at both the transcriptional and translational level, some of which are being developed for potential clinical use in a variety of human diseases. Named a pioneer in the field of Biomarker Medicine by the Journal of the National Cancer Institute, she created a Proteomics Initiative at Boston Children’s Hospital, has utilized its resources, including an extensive human biorepository and has leveraged her significant expertise in proteomics, to discover and validate a number of novel, non-invasive biomarkers for a variety of human cancers and non-neoplastic diseases. Several of these biomarkers are currently being used in clinical trials. Dr. Moses and her team have engineered novel, actively targeted, precision nanomedicines for the treatment of human cancers and their metastases. A number of these therapeutics and diagnostics are included in Dr. Moses’ significant patent portfolio composed of both US and foreign patents.

Dr. Moses’ basic and translational work has been published in such journals as Science, The New England Journal of Medicine, Cell, PNAS and Nature Communications, among others. She received a Ph.D. in Biochemistry from Boston University and completed a National Institutes of Health postdoctoral fellowship at Boston Children's Hospital and MIT in the laboratory of Dr. Robert Langer. Dr. Moses is the recipient of a number of NIH and foundation grants and numerous awards and honors. She has been recognized with both of Harvard Medical School's mentoring awards, the A. Clifford Barger Mentoring Award and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty. Marsha has received the Excellence in Mentoring Award from the Postdoc Association of Boston Children’s Hospital and has also received their Award for Exceptional Mentorship. She has also received the Honorary Member Mentoring Award from the Association of Women Surgeons of the American College of Surgeons.

Dr. Moses has been elected to the Institute of Medicine (National Academy of Medicine) of the National Academies of the United States, the National Academy of Inventors, the American Institute for Medical and Biological Engineering and is a Fellow of the American Association for the Advancement of Science. She is the 2021 recipient of the American Association for Cancer Research (AACR)-Women in Cancer Research Charlotte Friend Lectureship.

  1. How breast cancer uses exosomes to metastasize to the brain.
  2. Novel CRISPR system could halt growth of triple-negative breast cancer
  3. Dually-targeted liposomes curb triple-negative breast cancer, metastases in mice
  4. The softer the nanoparticle, the better the drug delivery to tumors
  5. Flipping the switch on tumor growth
  6. Helping tissue grafts build a blood supply: Less is more
  7. How do you define innovation? Part IV
  8. Can breast cancer run on cholesterol?
  9. Breast cancer and estrogen: Blocking ADAM to save Eve

Selected Publications

  1. Morad G, Carmen CV, Hagedorn EJ, Perlin JR, Zon LI, Mustafaoglu M. Park T-E, Ingber DI, Daisy CC, Moses MA. Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. 2019, ACS Nano, 2019; September 10, In Press, PMID:31479239 (Selected for Cover Feature).
  2. Guo P, Yang J, Huang J, Auguste DT#, Moses MA#. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Proceedings of the National Academy of Sciences USA 2019; 116(37):18295-18303 (#These authors contributed equally and are co-last authors) PMID: 31451668.
  3. Huang J, Gao P*, Moses MA*. Rationally designed antibody drug conjugates targeting the breast cancer-association endothelium. ACS Biomaterials Science & Engineering 2019; In Press (*Co-corresponding authors)
  4. Morad G, Moses MA. Brainwashed by extracellular vesicles: The role of extracellular vesicles in primary and metastatic brain tumor microenvironment. Journal of Extracellular Vesicles, 2019; 8(1):1627164 PMID: 31275532.
  5. Guo P, Liu D, Subramanyam K, Wang B, Yang J, Huang J, Auguste DT*+, Moses MA*+. Nanoparticle elasticity directs tumor uptake. Nature Communications 2018; 9(1):130, January 9. PMID: 29317633. PMCID:PMC5760638 (*These authors contributed equally to this work and are co-last authors.) (+Co-corresponding authors.)
  6. Guo P, Wang B, Liu D, Yang J, Subramanyam K, McCarthy CR, Hebert J, Moses MA*, Auguste DT*. Using atomic force microscopy to predict tumor specificity of ICAM1 antibody-directed nanomedicines. Nano Letters March 2018; 18(4):2254-2262. PMID: 29505261. (*These authors contributed equally and are co-last authors.)
  7. Gordon LB, Campbell SE, Massaro J, D’Agostino RB, Kleinman ME, Kieran MW, Moses MA. A survey of plasma proteins in children with Progeria pre-therapy and on-therapy with Lonafarnib. Pediatric Research May 2018; 83(5):982-992. PMID: 29342131.
  8. Roy R, Dagher A, Butterfield C, Moses, MA. ADAM12 is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling. Molecular Cancer Research, 2017; 15(11):1608-1622. PMID: 28765266 PMCID: PMC5668165.
  9. Guo P*, Yang J*, Bielenberg DR, Dillon D, Zurakowski D, Moses MA+, Auguste DT+. A quantitative method for screening and identifying molecular targets for nanomedicine. J Controlled Release 2017; 263:57-67. pii: S0168-3659(17):30141-4. doi: 10.1016/j.jconrel.2017.03.030. [Epub ahead of print] PMID: 28341549 (*These authors contributed equally to this work.) (+These authors contributed equally to this work and are co-last authors.)
  10. Guo P+, Yang J+, Jia D, Moses MA*,•, Auguste DT*,•. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-Angiogenic Agents for Triple Negative Breast Cancer. Theranostics 2016 Jan 1; 6(1):1-13. PMID: 26722369. PMCID: PMC4679350 (+These authors contributed equally to this work and are co-first authors) (*,•These authors contributed equally to this work and are co-last authors)
  11. Jedinak A, Curatolo A, Zurakowski D, Dillon S, Bhasin MK, Libermann TA, Roy R, Sachdev M, Loughlin KR, Moses MA. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer 2015 Apr 11; 15(1):259 PMID: 25884438. PMCID: PMC4433087.
  12. Jia D, Huang L, Bischoff J, Moses MA. The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells. FASEB J. 2015 Apr; 29(4):1371-1382 (Epub 2015 July 19) PMID: 25550468. PMCID: PMC4734806.
  13. Roy R, Zurakowski D, Wischhusen J, Frauenhoffer C, Hooshmand S, Kulke M, Moses MA. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer 2014 Oct 28; 111(9):1772-1779 (Epub 2014 Aug 19). PMID: 25137018 PMCID: PMC4453724.
  14. Guo P*, Huang J*, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA, Auguste DT. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A 2014 Oct 14; 111(41):14710-14715 (Epub 2014 Sep 29 ) (*These authors contributed equally to this work.) PMID: 25267626. PMCID: PMC4205631.
  15. Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, Moses MA. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol 2014 Jul; 184(7):2099-20110. PMCID: PMC4076468.
  16. Jia D, Hasso SM, Chan J, D’Amore, Zurakowski D, Rodig SJ, Moses MA. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood 2013 Jan 24; 121(4): 707-15; Epub 2012 Dec 3. PMCID: PMC3557646. (*Selected for Cover Feature)
  17. Yang J, McNeish B, Butterfield C, Moses MA. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J 2013; 27(1): 45-50. PMCID: PMC3528324.
  18. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley S, Mulholland D, Rotinen M, Hager MH, Insabato L, Moses MA, Demichelis F, Lisanti MP, Wu H, Klagsbrun M, Bhowmick NA, Rubin MA, D'Souza-Schorey C, Freeman MR. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol 2012 Nov; 181(15):1573-84. PMCID: PMC3483805.
  19. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA. ADAM12 transmembrane and secreted isoforms promote breast tumor growth and metastasis. J Biol Chem 2011 Jun 10; 286(23); Epub 2011 Apr 14. PMCID: PMC3121517.
  20. Fernandez CA, Roy R, Lee S, Yang J, Panigrahy D, Van Vliet KJ, Moses MA. The anti-angiogenic peptide, Loop 6, binds IGF-IR. J Biol Chem 2010 Dec 31; 285(53); Epub 2010 Oct 12. PMCID: PMC3009916.
  21. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Kung AL, Zurakowski D, Moses MA. Neutrophil gelatinase-associated lipocalin promotes breast cancer progression: mechanistic studies and clinical implications. PNAS 2009; 106(10): 3913-3918. PMCID: PMC2656179.
  22. Harper J, Yan L, Louriero R, Wu I, Fang J, D'Amore P, Moses MA. Repression of VEGF expression by the zinc finger transcription factor ZNF24. Cancer Res 2007; 67(18):8736-41.
  23. Pories SE, Zurakowski D, Roy R, Lamb CC, Raza S, Exarhopoulos A, Scheib RG, Schumer S, Lenahan C, Borges V, Louis GW, Anand A, Isakovich N, Hirschfield-Bartek J, Wewer U, Lotz MM, Moses MA. Urinary metalloproteinases: noninvasive biomarkers of breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev 2008; 17(5):1034-42.
  24. Smith ER, Manfredi M, Scott RM, Black P, Moses MA. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery 2007; 60(6):E1148-9.


Publications powered by Harvard Catalyst Profiles

  1. A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer. Adv Sci (Weinh). 2020 Dec; 7(24):2002852. View abstract
  2. Association of Longitudinal Changes in Symptoms and Urinary Biomarkers in Patients with Urological Chronic Pelvic Pain Syndrome: A MAPP Research Network Study. J Urol. 2021 02; 205(2):514-523. View abstract
  3. Cancer Nanomedicines in an Evolving Oncology Landscape. Trends Pharmacol Sci. 2020 10; 41(10):730-742. View abstract
  4. Platelet-derived extracellular vesicles infiltrate and modify the bone marrow during inflammation. Blood Adv. 2020 07 14; 4(13):3011-3023. View abstract
  5. Cdc42-Dependent Transfer of mir301 from Breast Cancer-Derived Extracellular Vesicles Regulates the Matrix Modulating Ability of Astrocytes at the Blood-Brain Barrier. Int J Mol Sci. 2020 May 28; 21(11). View abstract
  6. Rationally Designed Antibody Drug Conjugates Targeting the Breast Cancer-Associated Endothelium. ACS Biomater Sci Eng. 2020 05 11; 6(5):2563-2569. View abstract
  7. Adipocytes promote ovarian cancer chemoresistance. Sci Rep. 2019 09 16; 9(1):13316. View abstract
  8. Tumor-Derived Extracellular Vesicles Breach the Intact Blood-Brain Barrier via Transcytosis. ACS Nano. 2019 12 24; 13(12):13853-13865. View abstract
  9. Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel. Proc Natl Acad Sci U S A. 2019 09 10; 116(37):18295-18303. View abstract
  10. Quantitative Analysis of Different Cell Entry Routes of Actively Targeted Nanomedicines Using Imaging Flow Cytometry. Cytometry A. 2019 08; 95(8):843-853. View abstract
  11. Brainwashed by extracellular vesicles: the role of extracellular vesicles in primary and metastatic brain tumour microenvironment. J Extracell Vesicles. 2019; 8(1):1627164. View abstract
  12. Metalloproteinases and their roles in human cancer. Anat Rec (Hoboken). 2020 06; 303(6):1557-1572. View abstract
  13. ITGA2 as a potential nanotherapeutic target for glioblastoma. Sci Rep. 2019 04 17; 9(1):6195. View abstract
  14. Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis. Sci Adv. 2019 03; 5(3):eaav5010. View abstract
  15. Physical and Family History Variables Associated With Neurological and Cognitive Development in Sturge-Weber Syndrome. Pediatr Neurol. 2019 07; 96:30-36. View abstract
  16. Changes in brain white matter structure are associated with urine proteins in urologic chronic pelvic pain syndrome (UCPPS): A MAPP Network study. PLoS One. 2018; 13(12):e0206807. View abstract
  17. Approaches to the discovery of non-invasive urinary biomarkers of prostate cancer. Oncotarget. 2018 Aug 21; 9(65):32534-32550. View abstract
  18. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. Pediatr Res. 2018 05; 83(5):982-992. View abstract
  19. Nanomaterial Preparation by Extrusion through Nanoporous Membranes. Small. 2018 05; 14(18):e1703493. View abstract
  20. A Time-lapse, Label-free, Quantitative Phase Imaging Study of Dormant and Active Human Cancer Cells. J Vis Exp. 2018 02 16; (132). View abstract
  21. Nanoparticle elasticity directs tumor uptake. Nat Commun. 2018 01 09; 9(1):130. View abstract
  22. ADAM12 Is a Novel Regulator of Tumor Angiogenesis via STAT3 Signaling. Mol Cancer Res. 2017 11; 15(11):1608-1622. View abstract
  23. Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng. 2017; 1. View abstract
  24. Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget. 2017 Apr 25; 8(17):29247-29257. View abstract
  25. Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. BJU Int. 2017 07; 120(1):130-142. View abstract
  26. A quantitative method for screening and identifying molecular targets for nanomedicine. J Control Release. 2017 Oct 10; 263:57-67. View abstract
  27. Characterization of dormant and active human cancer cells by quantitative phase imaging. Cytometry A. 2017 05; 91(5):424-432. View abstract
  28. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer. Theranostics. 2016; 6(1):1-13. View abstract
  29. A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst. 2015 Sep; 31(9):1433-45. View abstract
  30. Mining the Human Proteome: Biomarker Discovery for Human Cancer and Metastases. Cancer J. 2015 Jul-Aug; 21(4):327-36. View abstract
  31. The GPR 55 agonist, L-a-lysophosphatidylinositol, mediates ovarian carcinoma cell-induced angiogenesis. Br J Pharmacol. 2015 Aug; 172(16):4107-18. View abstract
  32. Infantile hemangioma-derived stem cells and endothelial cells are inhibited by class 3 semaphorins. Biochem Biophys Res Commun. 2015 Aug 14; 464(1):126-32. View abstract
  33. Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer. BMC Cancer. 2015 Apr 11; 15:259. View abstract
  34. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila). 2015 Mar; 8(3):240-8. View abstract
  35. The endogenous zinc finger transcription factor, ZNF24, modulates the angiogenic potential of human microvascular endothelial cells. FASEB J. 2015 Apr; 29(4):1371-82. View abstract
  36. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A. 2014 Oct 14; 111(41):14710-5. View abstract
  37. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol. 2014 Jul; 184(7):2099-110. View abstract
  38. Matrilin-1 is an inhibitor of neovascularization. J Biol Chem. 2014 May 16; 289(20):14301-9. View abstract
  39. Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm. 2014 Mar 03; 11(3):755-65. View abstract
  40. Urine vascular biomarkers in Sturge-Weber syndrome. Vasc Med. 2013 Jun; 18(3):122-8. View abstract
  41. Transcriptional repression of VEGF by ZNF24: mechanistic studies and vascular consequences in vivo. Blood. 2013 Jan 24; 121(4):707-15. View abstract
  42. Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol. 2012 Nov; 181(5):1573-84. View abstract
  43. Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer. FASEB J. 2013 Jan; 27(1):45-50. View abstract
  44. Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials. 2012 Nov; 33(32):8104-10. View abstract
  45. Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg. 2012 Nov; 94(5):1509-17. View abstract
  46. Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vasc Cell. 2012 Jul 05; 4(1):11. View abstract
  47. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 2012 May 06; 12:169. View abstract
  48. Forty-year journey of angiogenesis translational research. Sci Transl Med. 2011 Dec 21; 3(114):114rv3. View abstract
  49. Potential of fluorescent metalloproteinase substrates for cancer detection. Clin Biochem. 2011 Dec; 44(17-18):1434-9. View abstract
  50. Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol. 2011 Nov; 123(2):295-300. View abstract
  51. Age-dependent loss of MMP-3 in Hutchinson-Gilford progeria syndrome. J Gerontol A Biol Sci Med Sci. 2011 Nov; 66(11):1201-7. View abstract
  52. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig. 2011 Jun; 4(1):26-33. View abstract
  53. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest. 2011 May; 121(5):1894-904. View abstract
  54. ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem. 2011 Jun 10; 286(23):20758-68. View abstract
  55. A role for cysteine-rich 61 in the angiogenic switch during the estrous cycle in cows: regulation by prostaglandin F2alpha. Biol Reprod. 2011 Aug; 85(2):261-8. View abstract
  56. ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat. 2012 Feb; 131(3):731-41. View abstract
  57. The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptor. J Biol Chem. 2010 Dec 31; 285(53):41886-95. View abstract
  58. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies. Respir Med. 2010 Jul; 104 Suppl 1:S45-58. View abstract
  59. Correlation between prenatal urinary matrix metalloproteinase activity and the degree of kidney damage in a large animal model of congenital obstructive uropathy. J Pediatr Surg. 2010 Jun; 45(6):1120-5. View abstract
  60. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23. View abstract
  61. Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood. 2010 Oct 28; 116(17):3367-71. View abstract
  62. Matrix metalloproteinases are elevated in the urine of patients with endometriosis. Fertil Steril. 2010 Nov; 94(6):2343-6. View abstract
  63. Effects of metalloproteinase inhibition in a murine model of renal ischemia-reperfusion injury. Pediatr Res. 2010 Mar; 67(3):257-62. View abstract
  64. Prenatal urinary matrix metalloproteinase profiling as a potential diagnostic tool in fetal obstructive uropathy. J Pediatr Surg. 2010 Jan; 45(1):70-3. View abstract
  65. Endothelial progenitor cells as a sole source for ex vivo seeding of tissue-engineered heart valves. Tissue Eng Part A. 2010 Jan; 16(1):257-67. View abstract
  66. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009 Nov 01; 27(31):5287-97. View abstract
  67. Lipocalin 2: a multifaceted modulator of human cancer. . 2009 Aug; 8(15):2347-52. View abstract
  68. VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res. 2009 May 15; 69(10):4537-44. View abstract
  69. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol. 2010 Feb; 42(2):227-34. View abstract
  70. Matrix metalloproteinases in the urine and tissue of patients with juvenile polyps: potential biomarkers for the presence of polyps. J Pediatr Gastroenterol Nutr. 2009 Apr; 48(4):405-11. View abstract
  71. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A. 2009 Mar 10; 106(10):3913-8. View abstract
  72. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008 Oct 15; 14(20):6610-7. View abstract
  73. Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw. 2008 Sep; 6(8):795-802. View abstract
  74. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2008 Aug; 14(8):1091-6. View abstract
  75. Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1034-42. View abstract
  76. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008 Apr 15; 14(8):2378-86. View abstract
  77. Obituary: M. Judah Folkman (1933-2008). Nature. 2008 Feb 14; 451(7180):781. View abstract
  78. A critical role for matrix metalloproteinases in liver regeneration. J Surg Res. 2008 Apr; 145(2):192-8. View abstract
  79. Influence of the surface structure of a multiblock copolymer on the cellular behavior of primary cell cultures of the upper aerodigestive tract in vitro. J Biomed Mater Res A. 2007 Nov; 83(2):558-69. View abstract
  80. Repression of vascular endothelial growth factor expression by the zinc finger transcription factor ZNF24. Cancer Res. 2007 Sep 15; 67(18):8736-41. View abstract
  81. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci U S A. 2007 Jun 12; 104(24):10010-5. View abstract
  82. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery. 2007 Jun; 60(6):E1148-9; discussion E1149. View abstract
  83. Establishment and biochemical characterization of primary cells of the upper aerodigestive tract. Clin Hemorheol Microcirc. 2007; 36(1):47-64. View abstract
  84. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model. Am J Physiol Gastrointest Liver Physiol. 2006 Dec; 291(6):G1011-9. View abstract
  85. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med. 2006 Jun 15; 354(24):2621-2. View abstract
  86. Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun. 2006 Jun 23; 345(1):523-9. View abstract
  87. Extracellular matrix dynamics associated with tissue-engineered intravascular sclerotherapy. J Pediatr Surg. 2006 Apr; 41(4):757-62. View abstract
  88. Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg. 2006 Apr; 56(4):418-22. View abstract
  89. Biocompatibility testing of novel multifunctional polymeric biomaterials for tissue engineering applications in head and neck surgery: an overview. Eur Arch Otorhinolaryngol. 2006 Mar; 263(3):215-22. View abstract
  90. Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res. 2006 Mar 10; 312(5):608-22. View abstract
  91. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS. 2006; (96):223-68. View abstract
  92. Vascular endothelial growth factor delays onset of failure in pressure-overload hypertrophy through matrix metalloproteinase activation and angiogenesis. Basic Res Cardiol. 2006 May; 101(3):204-13. View abstract
  93. Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. Chest. 2005 Dec; 128(6 Suppl):572S. View abstract
  94. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005 Aug 01; 11(15):5390-5. View abstract
  95. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics. 2005 Jul; 116(1):38-45. View abstract
  96. [Cell proliferation and cellular activity of primary cell cultures of the oral cavity after cell seeding on the surface of a degradable, thermoplastic block copolymer]. Biomed Tech (Berl). 2005 Apr; 50(4):92-9. View abstract
  97. Matrix metalloproteinase-2 (MMP-2) expression and regulation by tumor necrosis factor alpha (TNFalpha) in the bovine corpus luteum. Mol Reprod Dev. 2005 Feb; 70(2):122-32. View abstract
  98. Expression of MMPs and TIMPs in primary epithelial cell cultures of the upper aerodigestive tract seeded on the surface of a novel polymeric biomaterial. Clin Hemorheol Microcirc. 2005; 32(2):117-28. View abstract
  99. Endothelial cells as mechanical transducers: enzymatic activity and network formation under cyclic strain. Mech Chem Biosyst. 2004 Dec; 1(4):279-90. View abstract
  100. Urinary matrix metalloproteinases and their endogenous inhibitors predict hepatic regeneration after murine partial hepatectomy. Transplantation. 2004 Oct 27; 78(8):1139-44. View abstract
  101. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem. 2004 Dec 03; 279(49):51323-30. View abstract
  102. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A. 2004 Aug 10; 101(32):11658-63. View abstract
  103. Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol. 2004 Feb 01; 22(3):499-506. View abstract
  104. A role for antiangiogenic therapy in breast cancer. Curr Oncol Rep. 2004 Jan; 6(1):42-8. View abstract
  105. Weight loss-induced calciphylaxis: potential role of matrix metalloproteinases. J Dermatol. 2003 Dec; 30(12):915-9. View abstract
  106. Temporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteum. Reprod Biol Endocrinol. 2003 Nov 07; 1:85. View abstract
  107. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell. 2003 Nov; 4(5):337-41. View abstract
  108. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem. 2003 Oct 17; 278(42):40989-95. View abstract
  109. Effect of pulse rate on collagen deposition in the tissue-engineered blood vessel. Tissue Eng. 2003 Aug; 9(4):579-86. View abstract
  110. BNF-1, a novel gene encoding a putative extracellular matrix protein, is overexpressed in tumor tissues. Gene. 2003 Jun 05; 311:105-10. View abstract
  111. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003 Apr 15; 63(8):1990-3. View abstract
  112. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem. 2003 Mar 14; 278(11):9790-5. View abstract
  113. The importance of angiogenesis in the interaction between polymeric biomaterials and surrounding tissue. Clin Hemorheol Microcirc. 2003; 28(3):175-81. View abstract
  114. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. Methods Mol Med. 2003; 74:375-90. View abstract
  115. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest. 2002 Oct; 110(7):923-32. View abstract
  116. Bovine membrane-type 1 matrix metalloproteinase: molecular cloning and expression in the corpus luteum. Biol Reprod. 2002 Jul; 67(1):99-106. View abstract
  117. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):715-20. View abstract
  118. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 2001 Oct 05; 276(40):37258-65. View abstract
  119. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. Cancer Res. 2001 Aug 01; 61(15):5731-5. View abstract
  120. A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma. Am J Pathol. 2001 Apr; 158(4):1185-90. View abstract
  121. Dynamics of extracellular matrix production and turnover in tissue engineered cardiovascular structures. J Cell Biochem. 2001 Mar 26; 81(2):220-8. View abstract
  122. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001 Mar 01; 61(5):2207-11. View abstract
  123. Cloning of a cDNA encoding an isoform of human protein phosphatase inhibitor 2 from vascularized breast tumor. DNA Seq. 2001; 11(6):515-8. View abstract
  124. Patch augmentation of the pulmonary artery with bioabsorbable polymers and autologous cell seeding. J Thorac Cardiovasc Surg. 2000 Dec; 120(6):1158-67; discussion 1168. View abstract
  125. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 2000 Dec; 157(6):1937-45. View abstract
  126. Adhesion-dependent control of matrix metalloproteinase-2 activation in human capillary endothelial cells. J Cell Sci. 2000 Nov; 113 ( Pt 22):3979-87. View abstract
  127. Angiogenic molecules and mechanisms in breast cancer. Curr Oncol Rep. 2000 Nov; 2(6):566-71. View abstract
  128. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A. 2000 Apr 11; 97(8):3884-9. View abstract
  129. Taste perception after lingual nerve repair. J Oral Maxillofac Surg. 2000 Jan; 58(1):3-5; discussion 5-6. View abstract
  130. The generation of endostatin is mediated by elastase. Cancer Res. 1999 Dec 15; 59(24):6052-6. View abstract
  131. Tissue engineering of autologous aorta using a new biodegradable polymer. Ann Thorac Surg. 1999 Dec; 68(6):2298-304; discussion 2305. View abstract
  132. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem. 1999 Oct 08; 274(41):29568-71. View abstract
  133. Fetal partial urethral obstruction causes renal fibrosis and is associated with proteolytic imbalance. J Urol. 1999 Sep; 162(3 Pt 1):854-60. View abstract
  134. Molecular angiogenesis. Chem Biol. 1999 Aug; 6(8):R217-24. View abstract
  135. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J Cell Sci. 1999 May; 112 ( Pt 10):1599-609. View abstract
  136. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A. 1999 Mar 16; 96(6):2645-50. View abstract
  137. Extracellular calcium influx stimulates metalloproteinase cleavage and secretion of heparin-binding EGF-like growth factor independently of protein kinase C. J Cell Biochem. 1998 May 01; 69(2):143-53. View abstract
  138. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998 Apr 01; 58(7):1395-9. View abstract
  139. Molecular cloning and expression analysis of the cDNA encoding rat tissue inhibitor of metalloproteinase-4. Matrix Biol. 1998 Jan; 16(6):339-42. View abstract
  140. Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J Biol Chem. 1997 Dec 12; 272(50):31730-7. View abstract
  141. Dysregulated proteolytic balance as the basis of excess extracellular matrix in fibrotic disease. Am J Physiol. 1997 Jun; 272(6 Pt 2):R1960-5. View abstract
  142. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A. 1997 Feb 04; 94(3):861-6. View abstract
  143. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997; 15(3):180-9. View abstract
  144. Matrix metalloproteinases and their inhibitors in aqueous humor. Exp Eye Res. 1996 May; 62(5):481-90. View abstract
  145. Identification of matrix metalloproteinases and metalloproteinase inhibitors in bovine corpora lutea and their variation during the estrous cycle. J Anim Sci. 1996 Apr; 74(4):849-57. View abstract
  146. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem. 1996 Mar 01; 60(3):379-86. View abstract
  147. Cloning and expression of the cDNA encoding rat tissue inhibitor of metalloproteinase 3 (TIMP-3). Gene. 1996 Feb 12; 168(2):243-6. View abstract
  148. The role of growth factors in vascular cell development and differentiation. Int Rev Cytol. 1995; 161:1-48. View abstract
  149. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21; 79(2):315-28. View abstract
  150. Purification and characterization of two collagenase inhibitors from mouse sarcoma 180 conditioned medium. J Cell Biochem. 1994 Sep; 56(1):97-105. View abstract
  151. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem. 1994 May 06; 269(18):13472-9. View abstract
  152. Production of matrix metalloproteinases and a metalloproteinase inhibitor by swarm rat chondrosarcoma. Biochem Biophys Res Commun. 1994 Feb 28; 199(1):418-24. View abstract
  153. Heparinase inhibits neovascularization. Proc Natl Acad Sci U S A. 1994 Feb 15; 91(4):1524-8. View abstract
  154. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol. 1994; 59:471-82. View abstract
  155. A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol. 1993 Mar-Apr; 11 Suppl 8:S67-9. View abstract
  156. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol. 1992 Oct; 119(2):475-82. View abstract
  157. Metalloproteinase inhibition as a mechanism for the inhibition of angiogenesis. EXS. 1992; 61:146-51. View abstract
  158. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem. 1991 Nov; 47(3):230-5. View abstract
  159. Inhibitors of angiogenesis. Biotechnology (N Y). 1991 Jul; 9(7):630-4. View abstract
  160. Biocompatible controlled release polymers for delivery of polypeptides and growth factors. J Cell Biochem. 1991 Apr; 45(4):340-5. View abstract
  161. Identification of an inhibitor of neovascularization from cartilage. Science. 1990 Jun 15; 248(4961):1408-10. View abstract